drugset / Trial / NCT04113005
Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer
Phase 0
Unknown
10 enrolled
Sunnybrook Health Sciences Centre
Sunnybrook Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single site, prospective, Phase 1 pilot trial intended to evaluate the safety and tolerability of adding one IV dose of Desmopressin to CRPC subjects at least 30 minutes prior to commencing standard IV Docetaxel treatment7,8.
Timeline
- Start
- 2019-10-01
- Primary completion
- 2020-04-30
- Completion
- 2020-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desmopressin | Peptide | — | Intravenous |